The rationale of enhanced cell killing was also applied with the Antibody Drug Conjugate ABBV-399 directed against MET, which in pre-clinical experiments gave efficacy in MET-overexpressing but not gene-amplified tumor cells in contrast to the parental antibody ABT-700 that only had therapeutic activity in MET-amplified tumors [44]. This evidence concerns the gene MET and neoplasm.